These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21809300)

  • 1. [Normoalbuminuria at all costs?].
    Maggio M
    G Ital Nefrol; 2011; 28(4):354. PubMed ID: 21809300
    [No Abstract]   [Full Text] [Related]  

  • 2. Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies.
    Barzilay JI; Gao P; O'Donnell M; Mann JF; Anderson C; Fagard R; Probstfield J; Dagenais GR; Teo K; Yusuf S;
    Arch Intern Med; 2011 Jan; 171(2):142-50. PubMed ID: 21263104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ONTARGET still OFF-TARGET?
    Lambers Heerspink HJ; de Zeeuw D
    Circulation; 2011 Mar; 123(10):1049-51. PubMed ID: 21357820
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of angiotensin receptor blockers in diabetic nephropathy.
    Sharma AM; Weir MR
    Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?
    Onuigbo MA
    Int J Clin Pract; 2010 Sep; 64(10):1341-6. PubMed ID: 20716141
    [No Abstract]   [Full Text] [Related]  

  • 6. [Protective effect of antihypertensive agents on renal insufficiency (REIN, RENAAL, IDNT, AASK, etc)].
    Tsuchida H; Kimura K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():617-22. PubMed ID: 15171445
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal protection in diabetes.
    Hunter JD; Ravert PK; Lassetter JH; Williams M
    Adv NPs PAs; 2011 Jan; 2(1):25-9; quiz 30. PubMed ID: 21329229
    [No Abstract]   [Full Text] [Related]  

  • 8. Should Angiotensin converting enzyme inhibitors be used in children with type 1 diabetes and microalbuminuria?
    Almerie MQ; Williams RM; Acerini CL
    Arch Dis Child; 2008 Jul; 93(7):633-5. PubMed ID: 18285389
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical inquiries. Which medications benefit patients with diastolic heart failure?
    Crouse M; Flack D; Kerns JW; Martin L; Pham D; Sudireddy R; Knight K
    J Fam Pract; 2011 Feb; 60(2):101-2, 108. PubMed ID: 21301643
    [No Abstract]   [Full Text] [Related]  

  • 10. [Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
    Feldt-Rasmussen BF
    Ugeskr Laeger; 2002 Apr; 164(14):1907-9. PubMed ID: 11957423
    [No Abstract]   [Full Text] [Related]  

  • 11. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 12. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema.
    Beavers CJ; Dunn SP; Macaulay TE
    Ann Pharmacother; 2011 Apr; 45(4):520-4. PubMed ID: 21427294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preserving the diabetic kidney.
    Poirier SJ
    J Fam Pract; 1998 Jan; 46(1):21-7. PubMed ID: 9451365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reviewing the benefits of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy--are they drug specific or class specific?
    Burgess E
    Can J Cardiol; 2010 Dec; 26 Suppl E():15E-19E. PubMed ID: 21620286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
    Tocci G; Paneni F; Palano F; Sciarretta S; Ferrucci A; Kurtz T; Mancia G; Volpe M
    Am J Hypertens; 2011 May; 24(5):582-90. PubMed ID: 21331058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
    Sanada S; Kitakaze M
    Nihon Rinsho; 2003 May; 61(5):821-6. PubMed ID: 12755009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical inquiries. Does screening for microalbuminuria in diabetes prevent complications?
    Hale WA; Nashelsky J; Wilson SA
    J Fam Pract; 2003 Mar; 52(3):229-31. PubMed ID: 12620179
    [No Abstract]   [Full Text] [Related]  

  • 19. Of fads, fashion, surrogate endpoints and dual RAS blockade.
    Messerli FH; Staessen JA; Zannad F
    Eur Heart J; 2010 Sep; 31(18):2205-8. PubMed ID: 20685681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS blockade: new possibilities in the treatment of complications of diabetes.
    Ruilope L
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i32-4:discussion i50. PubMed ID: 10956319
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.